A H Barnett
Overview
Explore the profile of A H Barnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
301
Citations
4957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OHare J, Hanif W, Millar-Jones D, Bain S, Hicks D, Leslie R, et al.
Diabet Med
. 2015 Sep;
32(11):1398-403.
PMID: 26331592
No abstract available.
2.
Altaf Q, Barnett A, Tahrani A
Diabetes Obes Metab
. 2014 Oct;
17(4):319-34.
PMID: 25308775
Insulin resistance (IR) plays an important role in the pathogenesis of type 2 diabetes (T2D) and cardiovascular disease. Hence improving IR is a major target of treatment in patients with...
3.
Lloyd C, Mughal S, Roy T, Raymond N, OHare J, Barnett A, et al.
Diabet Med
. 2014 Jul;
31(12):1600-9.
PMID: 25073479
Aims: To investigate concordance with medication, as assessed at baseline and at 1- and 2-year follow-up, and to examine factors associated with non-concordance in a UK-resident South-Asian population. Methods: Data...
4.
Schernthaner G, Barnett A, Patel S, Hehnke U, von Eynatten M, Woerle H
Diabetes Obes Metab
. 2014 May;
16(11):1078-86.
PMID: 24865132
Aims: To investigate individual patient data from a comprehensive trials programme to evaluate the safety and efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin across a range of glucose-lowering regimens...
5.
Munro N, Barnett A
Int J Clin Pract
. 2014 Feb;
68(6):692-9.
PMID: 24548693
Aims: The Global Attitude of Patients and Physicians 2 (GAPP2) survey sought to address gaps in understanding about real-world basal insulin-taking behaviour and self-treated hypoglycaemia in patients with type 2...
6.
Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, et al.
Diabetes Obes Metab
. 2013 Nov;
16(5):433-42.
PMID: 24237939
Aims: Indirect evidence from randomized controlled trials (RCTs) was used to estimate the effect of dapagliflozin, a new agent with a novel mechanism of action (SGLT-2 inhibition), relative to other...
7.
Burmeister A, Assi L, Ferro C, Hughes R, Barnett A, Bellary S, et al.
Int J Lab Hematol
. 2013 Nov;
36(4):415-24.
PMID: 24188493
Introduction: Serum concentrations of polyclonal free light chains (FLC) represent the activity of the adaptive immune system. This study assessed the relationship between polyclonal FLC and the established marker of...
8.
Mathieu C, Barnett A, Brath H, Conget I, de Castro J, Goke R, et al.
Int J Clin Pract
. 2013 Aug;
67(10):947-56.
PMID: 23961850
Aim: Real-life studies are needed to confirm the clinical relevance of findings from randomised controlled trials (RCTs). This study aimed to assess the effectiveness and tolerability of vildagliptin add-on vs....
9.
Barnett A, Brice R, Hanif W, James J, Langerman H
Curr Med Res Opin
. 2013 Aug;
29(11):1503-13.
PMID: 23952328
Hypoglycaemia is the most common acute complication of type 2 diabetes and can limit therapeutic efforts to improve glycaemic control in order to protect against long-term complications. It is a...
10.
Holden S, Barnett A, Peters J, Jenkins-Jones S, Poole C, Morgan C, et al.
Diabetes Obes Metab
. 2013 May;
15(9):844-52.
PMID: 23675742
Aims: To characterize the incidence of type 2 diabetes in the UK over the previous 20 years; and determine if there has been an increase in people aged 40 years...